Edition:
United Kingdom

Takeda Pharmaceutical Co Ltd (4502.T)

4502.T on Tokyo Stock Exchange

6,183JPY
24 Nov 2017
Change (% chg)

¥28 (+0.45%)
Prev Close
¥6,155
Open
¥6,155
Day's High
¥6,193
Day's Low
¥6,120
Volume
1,374,700
Avg. Vol
2,023,882
52-wk High
¥6,464
52-wk Low
¥4,555

Select another date:

Wed, Nov 15 2017

BRIEF-U.S. FDA provides new drug safety communication on Takeda's gout drug

* U.S. FDA says preliminary results from a safety clinical trial show increased risk of heart-related death with Febuxostat (Uloric) versus Allopurinol

BRIEF-TAKEDA RECEIVES POSITIVE CHMP OPINION FOR ADCETRIS FOR CD30-POSITIVE CUTANEOUS T-CELL LYMPHOMA

* TAKEDA RECEIVES POSITIVE CHMP OPINION FOR ADCETRIS® (BRENTUXIMAB VEDOTIN) FOR CD30-POSITIVE CUTANEOUS T-CELL LYMPHOMA

Takeda takes on Sanofi with new global dengue vaccine data

Takeda Pharmaceutical's experimental dengue vaccine has produced promising long-term results in clinical tests, boosting the Japanese company's global hopes for a product that will take on Sanofi's Dengvaxia.

Takeda takes on Sanofi with new global dengue vaccine data

Nov 7 Takeda Pharmaceutical's experimental dengue vaccine has produced promising long-term results in clinical tests, boosting the Japanese company's global hopes for a product that will take on Sanofi's Dengvaxia.

BRIEF-Takeda and HemoShear Therapeutics enter drug discovery partnership in liver diseases

* Takeda and HemoShear Therapeutics enter into exclusive drug discovery partnership in liver diseases

BRIEF-Takeda gets FDA approval for ALUNBRIG 180 mg tablets

* Takeda announces FDA approval of ALUNBRIG (brigatinib) 180 mg tablets

BRIEF-Takeda, SGC in collaboration agreement related to inflammatory bowel disease

* Takeda and SGC announce a collaboration agreement using patient tissue-based assays for clinical target validation in inflammatory bowel disease

AstraZeneca strikes $400 million Parkinson's drug deal with Takeda

LONDON AstraZeneca is to receive up to $400 million from Takeda Pharmaceutical after striking a deal for the Japanese company to co-develop an early-stage medicine for Parkinson's disease.

AstraZeneca strikes $400 million Parkinson's drug deal with Takeda

LONDON AstraZeneca is to receive up to $400 million from Takeda Pharmaceutical after striking a deal for the Japanese company to co-develop an early-stage medicine for Parkinson's disease.

AstraZeneca strikes $400 mln Parkinson's drug deal with Takeda

LONDON, Aug 29 AstraZeneca is to receive up to $400 million from Takeda Pharmaceutical after striking a deal for the Japanese company to co-develop an early-stage medicine for Parkinson's disease.

Select another date: